Cargando…
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. This limitation is exacerbated by a lack of robust biomarkers. In this study, w...
Autores principales: | Onieva, Juan Luis, Xiao, Qingyang, Berciano-Guerrero, Miguel-Ángel, Laborda-Illanes, Aurora, de Andrea, Carlos, Chaves, Patricia, Piñeiro, Pilar, Garrido-Aranda, Alicia, Gallego, Elena, Sojo, Belén, Gálvez, Laura, Chica-Parrado, Rosario, Prieto, Daniel, Pérez-Ruiz, Elisabeth, Farngren, Angela, Lozano, María José, Álvarez, Martina, Jiménez, Pedro, Sánchez-Muñoz, Alfonso, Oliver, Javier, Cobo, Manuel, Alba, Emilio, Barragán, Isabel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408876/ https://www.ncbi.nlm.nih.gov/pubmed/36012390 http://dx.doi.org/10.3390/ijms23169124 |
Ejemplares similares
-
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020) -
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma
por: Oliver, Javier, et al.
Publicado: (2022) -
Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer
por: Schmidt, Marcus, et al.
Publicado: (2021) -
Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade
por: Oliver, Javier, et al.
Publicado: (2023) -
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
por: Chica-Parrado, María Rosario, et al.
Publicado: (2020)